The European research effort for HIV/AIDS, malaria and tuberculosis

The global emergency caused by HIV/AIDS, malaria and tuberculosis requires for new approaches and actions to confront these three major poverty-related diseases. In response to this emergency, the European Commission provides a broad comprehensive approach in a wide range of policy areas, including trade, development and research. For research, the overall strategy is to develop new drugs, vaccines or other effective interventions by two main mechanisms: (i) support of research projects for the development of new promising candidates through pre-clinical and early human testing and (ii) establishment of a programme to support phases II and III clinical trials in Africa. The Sixth Framework Programme (FP6) (2002-2006) allocates a total of 400 million euro to research on HIV/AIDS, malaria and tuberculosis with about 200 million for each of the two interlinked components. Research projects, aiming at developing new promising candidates, should create large consortia capable of integrating different approaches and disciplines providing the necessary critical mass to test and compare different scientific ideas. Projects should cover different phases in the development process ranging from basic knowledge generated from genomics or immunology to pre-clinical testing in animal models and finally validation in safety trials. The new instruments, mainly Integrated Projects and Network of Excellence, are the preferred means to implement the proposed approach. The European and Developing Countries clinical trials partnership (EDCTP) will help to overcome the bottleneck of demonstrating a proof of principle for promising vaccine or drug candidates in testing them in early efficacy trials in endemic areas, particularly in sub-Saharan Africa